Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(25%)
Results Posted
125%(5 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_4
1
13%
Ph phase_2
4
50%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Active, not recruiting2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 41 (14.3%)

Trials by Status

active_not_recruiting225%
terminated113%
completed450%
unknown113%

Recent Activity

2 active trials
Showing 5 of 8
active_not_recruitingphase_2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
completedphase_2

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722
active_not_recruitingphase_2

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

NCT04439136
terminatedphase_2

Afatinib in Advanced Refractory Urothelial Cancer

NCT02122172
completedphase_1

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

NCT02364609
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02465060Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active Not Recruiting
NCT02438722Phase 2

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Completed
NCT04439136Phase 2

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Active Not Recruiting
NCT02122172Phase 2

Afatinib in Advanced Refractory Urothelial Cancer

Terminated
NCT02364609Phase 1

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Completed
NCT02451553Phase 1

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Completed
NCT04814056Phase 4

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Unknown
NCT02131259

Long-term Observation PMS for Afatinib

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8